Mouse Assay:Article Title: IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma
Article Snippet: .. Mice were injected intraperitoneally (i.p.) with 200 μg of specific monoclonal antibodies or inhibitors: anti-mouse CD8, InVivoPlus, clone YTS169.4 (BioXCell Cat. BP0117, RRID:AB_2894806) and the relative isotype control rat IgG2b, InVivoPlus, clone LTF-2 (BioXCell Cat. BP0090, RRID:AB_1107780); anti-mouse NK1.1, InVivoPlus, clone PK136 (BioXCell Cat. BP0036, RRID:AB_2894792) and the relative isotype control rat IgG2a, InVivoPlus, clone C1.18.4 (BioXCell Cat. BP0085, RRID:AB_1107771); anti-IFNInVivoPlus, clone XMG1.2 (BioXCell Cat. BP0055, RRID:AB_1107694) and the relative isotype control rat IgG1, InVivoPlus, clone HRPN (BioXCell Cat. BP0088, RRID:AB_1107775), the day before tumor cell transplantation. .. They were the injected i.p. with 100 μg once (anti-NK1.1), twice (anti-CD8) or three times (anti- IFNa week for the entire duration of the experiment; anti-mouse PD-1, InVivoPlus, clone RMP1- 14 (BioXCell, Cat. BP0146, RRID:AB_10949053) and the relative isotype control rat IgG2a, InVivoPlus, clone 2A3 (BioXCell, Cat. BP0089, RRID: AB_1107769), 200 μg twice a week, starting from 9 days after tumor cell injection.
Injection:Article Title: IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma
Article Snippet: .. Mice were injected intraperitoneally (i.p.) with 200 μg of specific monoclonal antibodies or inhibitors: anti-mouse CD8, InVivoPlus, clone YTS169.4 (BioXCell Cat. BP0117, RRID:AB_2894806) and the relative isotype control rat IgG2b, InVivoPlus, clone LTF-2 (BioXCell Cat. BP0090, RRID:AB_1107780); anti-mouse NK1.1, InVivoPlus, clone PK136 (BioXCell Cat. BP0036, RRID:AB_2894792) and the relative isotype control rat IgG2a, InVivoPlus, clone C1.18.4 (BioXCell Cat. BP0085, RRID:AB_1107771); anti-IFNInVivoPlus, clone XMG1.2 (BioXCell Cat. BP0055, RRID:AB_1107694) and the relative isotype control rat IgG1, InVivoPlus, clone HRPN (BioXCell Cat. BP0088, RRID:AB_1107775), the day before tumor cell transplantation. .. They were the injected i.p. with 100 μg once (anti-NK1.1), twice (anti-CD8) or three times (anti- IFNa week for the entire duration of the experiment; anti-mouse PD-1, InVivoPlus, clone RMP1- 14 (BioXCell, Cat. BP0146, RRID:AB_10949053) and the relative isotype control rat IgG2a, InVivoPlus, clone 2A3 (BioXCell, Cat. BP0089, RRID: AB_1107769), 200 μg twice a week, starting from 9 days after tumor cell injection.
Bioprocessing:Article Title: IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma
Article Snippet: .. Mice were injected intraperitoneally (i.p.) with 200 μg of specific monoclonal antibodies or inhibitors: anti-mouse CD8, InVivoPlus, clone YTS169.4 (BioXCell Cat. BP0117, RRID:AB_2894806) and the relative isotype control rat IgG2b, InVivoPlus, clone LTF-2 (BioXCell Cat. BP0090, RRID:AB_1107780); anti-mouse NK1.1, InVivoPlus, clone PK136 (BioXCell Cat. BP0036, RRID:AB_2894792) and the relative isotype control rat IgG2a, InVivoPlus, clone C1.18.4 (BioXCell Cat. BP0085, RRID:AB_1107771); anti-IFNInVivoPlus, clone XMG1.2 (BioXCell Cat. BP0055, RRID:AB_1107694) and the relative isotype control rat IgG1, InVivoPlus, clone HRPN (BioXCell Cat. BP0088, RRID:AB_1107775), the day before tumor cell transplantation. .. They were the injected i.p. with 100 μg once (anti-NK1.1), twice (anti-CD8) or three times (anti- IFNa week for the entire duration of the experiment; anti-mouse PD-1, InVivoPlus, clone RMP1- 14 (BioXCell, Cat. BP0146, RRID:AB_10949053) and the relative isotype control rat IgG2a, InVivoPlus, clone 2A3 (BioXCell, Cat. BP0089, RRID: AB_1107769), 200 μg twice a week, starting from 9 days after tumor cell injection.
Control:Article Title: IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma
Article Snippet: .. Mice were injected intraperitoneally (i.p.) with 200 μg of specific monoclonal antibodies or inhibitors: anti-mouse CD8, InVivoPlus, clone YTS169.4 (BioXCell Cat. BP0117, RRID:AB_2894806) and the relative isotype control rat IgG2b, InVivoPlus, clone LTF-2 (BioXCell Cat. BP0090, RRID:AB_1107780); anti-mouse NK1.1, InVivoPlus, clone PK136 (BioXCell Cat. BP0036, RRID:AB_2894792) and the relative isotype control rat IgG2a, InVivoPlus, clone C1.18.4 (BioXCell Cat. BP0085, RRID:AB_1107771); anti-IFNInVivoPlus, clone XMG1.2 (BioXCell Cat. BP0055, RRID:AB_1107694) and the relative isotype control rat IgG1, InVivoPlus, clone HRPN (BioXCell Cat. BP0088, RRID:AB_1107775), the day before tumor cell transplantation. .. They were the injected i.p. with 100 μg once (anti-NK1.1), twice (anti-CD8) or three times (anti- IFNa week for the entire duration of the experiment; anti-mouse PD-1, InVivoPlus, clone RMP1- 14 (BioXCell, Cat. BP0146, RRID:AB_10949053) and the relative isotype control rat IgG2a, InVivoPlus, clone 2A3 (BioXCell, Cat. BP0089, RRID: AB_1107769), 200 μg twice a week, starting from 9 days after tumor cell injection.
Transplantation Assay:Article Title: IL-1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma
Article Snippet: .. Mice were injected intraperitoneally (i.p.) with 200 μg of specific monoclonal antibodies or inhibitors: anti-mouse CD8, InVivoPlus, clone YTS169.4 (BioXCell Cat. BP0117, RRID:AB_2894806) and the relative isotype control rat IgG2b, InVivoPlus, clone LTF-2 (BioXCell Cat. BP0090, RRID:AB_1107780); anti-mouse NK1.1, InVivoPlus, clone PK136 (BioXCell Cat. BP0036, RRID:AB_2894792) and the relative isotype control rat IgG2a, InVivoPlus, clone C1.18.4 (BioXCell Cat. BP0085, RRID:AB_1107771); anti-IFNInVivoPlus, clone XMG1.2 (BioXCell Cat. BP0055, RRID:AB_1107694) and the relative isotype control rat IgG1, InVivoPlus, clone HRPN (BioXCell Cat. BP0088, RRID:AB_1107775), the day before tumor cell transplantation. .. They were the injected i.p. with 100 μg once (anti-NK1.1), twice (anti-CD8) or three times (anti- IFNa week for the entire duration of the experiment; anti-mouse PD-1, InVivoPlus, clone RMP1- 14 (BioXCell, Cat. BP0146, RRID:AB_10949053) and the relative isotype control rat IgG2a, InVivoPlus, clone 2A3 (BioXCell, Cat. BP0089, RRID: AB_1107769), 200 μg twice a week, starting from 9 days after tumor cell injection.
|